Investigation Questions Drug's Approval for Agitation in AD

The agency defended approval of brexpiprazole (Rexulti) for the treatment of agitation, saying the antipsychotic fills an unmet medical need.
Medscape Medical News

source https://www.medscape.com/viewarticle/995697?src=rss